Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine + lidocaine and postoperative immune function in lung cancer surgery
ChiCTR2300070292Phase 4Not yet recruiting
- Sponsor
- Tai'an City Central Hospital
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexmedetomidine and lidocaine in bronchial carcinoma (2 arms), sponsored by Tai'an City Central Hospital. Primary endpoint: IL-6. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
dexmedetomidinelidocaine
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2300070292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070292.